Where Moderna Stands With Analysts

Analysts' ratings for Moderna MRNA over the last quarter vary from bullish to bearish, as provided by 5 analysts.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $106.0, along with a high estimate of $142.00 and a low estimate of $82.00. This upward trend is apparent, with the current average reflecting a 21.14% increase from the previous average price target of $87.50.

Exploring Analyst Ratings: An In-Depth Overview

An in-depth analysis of recent analyst actions unveils how financial experts perceive Moderna. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Moderna. This offers insight into analysts' perspectives on the current state of the company.
• Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Moderna compared to the broader market.
• Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Moderna's stock. This comparison reveals trends in analysts' expectations over time.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Moderna's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on Moderna analyst ratings.

Unveiling the Story Behind Moderna

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Moderna: Delving into Financials

Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.

Decline in Revenue: Over the 3 months period, Moderna faced challenges, resulting in a decline of approximately -44.5% in revenue growth as of 30 September, 2023. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: Moderna's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -203.13%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Moderna's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -23.88%, the company may face hurdles in achieving optimal financial performance.

Return on Assets (ROA): Moderna's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -17.56%, the company may face hurdles in achieving optimal financial returns.

Debt Management: Moderna's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.11.

Understanding the Relevance of Analyst Ratings

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

This article was generated by Benzinga's automated content engine and reviewed by an editor.